Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Summary

The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied. Ipilimumab is designed to increase the immune system's ability to fight cancer. Abraxane is designed to stop cancer cells from making new DNA (the genetic material of cells). This may stop the cancer cells from dividing into new cells.

Timeline

Start

2013-04-25

Primary completion

2020-09-21

Completion

2020-09-21

Drugs

Indications